Morphic Therapeutic
Gustav Christensen was President and CEO of Dyax Corp (NASDAQ: DYAX) from January 1, 2009 till it was acquired by Shire for $6.5 billion in January 2016. He joined Dyax early 2007 as EVP and Chief Business Officer.
This person is not in the org chart
This person is not in any offices
Morphic Therapeutic
1 followers
Morphic Therapeutic is leading the development of a new generation of oral integrin drugs, informed by decades of world-leading expertise and a unique integrin discovery platform.